MDGH is developing two medicines: moxidectin and dovramilast.
Together, moxidectin and dovramilast are being investigated in seven different diseases that collectively have a global prevalence of more than a billion cases.
Our expertise is in the product development process, which we apply to advancing medicines and vaccines that address important unmet medical needs, predominantly in low- and middle-income countries. We work with global colleagues, collaborators and contributors at all stages of the process of investigating and implementing new and improved medicines for the treatment of neglected diseases.
INCLUSION IN WHO GUIDELINES
(CC-11050 or AMG 634)
*Stringent Regulatory Authority Approval
Moxidectin is a macrocyclic lactone and is from the same family as ivermectin, which is one of the most well-regarded medicines in the world today.
Dovramilast (previously known as CC-11050 or AMG 634) is a phosphodiesterase type 4 (PDE4) inhibitor from the same class of medicines as Otezla®, a well-known treatment for psoriasis, marketed by Amgen. Dovramilast modifies the host’s immune response to infection and is being studied for the treatment of tuberculosis and leprosy type 2 reactions.
You can find out more about our clinical trials by visiting the website below. The clinicaltrials.gov website, maintained by the US National Library of Medicine at the National Institutes of Health, provides access to publicly and privately supported clinical trials on nearly every type of disease and condition.